Abstract-Blood loss is a significant problem encountered in patients undergoing total joint arthroplasty, and is considered to be one of the factors affecting the outcome of the operation. Traditionally these patients have been treated with blood transfusions. The introduction of recombinant human erythropoietin (rHuEpo) into clinical practice enabled assessment of its effectiveness to decrease the allogeneic blood transfusion requirement (BTR), thus avoiding or minimizing transfusion-related complications.
INTRODUCTION
Major orthopedic surgery, especially total hip replacement (THR) and total knee replacement (TKR), are often associated with significant blood loss, leading to symptomatic anemia [1] . The prognosis and risk of a fatal outcome in these patients has been found to be related to the amount of blood loss and the degree of anemia [2] . The traditional way to treat the anemia has been blood transfusions. However, this approach has been associated with various immediate and late complications [3] [4] [5] . This study was undertaken in an attempt to study the efficacy of recombinant human erythropoietin (rHuEpo, Epoetin-alfa) in attenuating the anemia and reducing allogeneic blood transfusion requirements (BTR) of such patients.
PATIENTS AND METHODS
Fifteen patients scheduled for elective major orthopedic surgery in the Rabin Medical Center from January 1st-April 30th, 1997, entered the study. Ten patients underwent THR, and 5 patients underwent TKR. The inclusion criteria into the study included hemoglobin (Hb) levels of <15 g/ dl, normal routine serum biochemistry, including liver and renal function, and normal iron stores (serum ferritin >50 ng/ dl). Exclusion criteria were: (1) Clinical or laboratory evidence of dysfunction of any of the following systems: -cardiovascular, pulmonary, neurological, gastrointestinal, genitourinary, -hematological including blood coagulation. 
